Treatment - Cancer Currents Blog
Cancer treatment related news, with context from leading experts. Includes articles on new therapies, treatment side effects, and important trends in treatment-related research.
-
Can Some Women Treated for Endometrial Cancer Forgo Radiation after Surgery?Some women with endometrial cancer may be able to receive less intensive treatment, chemotherapy and no radiation, without increasing their risk of the disease recurring within 5 years, according to the results of a randomized clinical trial.
-
Trial Highlights Complexities of Targeted Therapy for Pancreatic CancerOlaparib (Lynparza) may be beneficial for some people with advanced pancreatic cancer who have inherited mutations in the BRCA1 or BRCA2 genes, according to results from the POLO trial.
-
More Treatment Options Emerging for Some Men with Metastatic Prostate CancerIn two large clinical trials, the drugs enzalutamide (Xtandi) and apalutamide (Erleada), respectively, combined with the androgen deprivation therapy, improved the survival of men with metastatic prostate cancer that still responds to hormone-suppressing therapies.
-
Combination Therapy with Venetoclax Approved for Chronic Lymphocytic LeukemiaThe Food and Drug Administration has approved venetoclax (Venclexta) in combination with obinutuzumab (Gazyva) for the initial treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
-
Drug Shows Promise in Slowing Progression of Smoldering Myeloma to CancerThe drug lenalidomide (Revlimid) may delay the progression of smoldering myeloma to multiple myeloma, according to preliminary results from a clinical trial.
-
T-DM1 Approval Expanded to Include Some Women with Early-Stage HER2-Positive Breast CancerFDA has expanded the approved use of the drug ado-trastuzumab emtansine (Kadcyla), also called T-DM1, to include adjuvant treatment in some women with early-stage HER2-positive breast cancer.
-
Tagraxofusp Proves Effective for BPDCN, A Rare Blood CancerNew findings from a clinical trial of the drug tagraxofusp confirm its efficacy against the rare blood cancer blastic plasmacytoid dendritic cell neoplasm (BPDCN).
-
New Drugs, New Side Effects: Complications of Cancer ImmunotherapyThe expanding use of cancer immunotherapy has revealed a variety of side effects associated with this treatment approach. Researchers are now trying to better understand how and why these side effects occur and develop strategies for better managing them.
-
Some Children with Liver Cancer May Need Less Chemotherapy, Study SuggestsSome children with liver cancer may need less chemotherapy than is typically used, new research suggests. The study included children and infants with hepatoblastoma whose tumors had been surgically removed when the disease was diagnosed.
-
A Vaccine to Treat Non-Hodgkin Lymphoma Advancing in Clinical TrialsIn some people with non-Hodgkin lymphoma (NHL), treating a single tumor with an in situ vaccine can help to shrink, or eliminate, tumors in other parts of the body, findings from a small clinical trial suggest.
-
Immunotherapy Drug with Two Targets Shows Promise against HPV-Related CancersThe investigational immunotherapy drug bintrafusp alfa (also called M7824), a bifunctional fusion protein, shrank the tumors of some patients with advanced HPV-related cancers, according to results from a phase 1 clinical trial.
-
Fewer Women with Ovarian, Breast Cancer Undergo Genetic Testing than ExpectedMany women diagnosed with ovarian and breast cancer are not undergoing tests for inherited genetic mutations that can provide important information to help guide decisions about treatment and longer-term cancer screening, a new study has found.
-
Researchers Discover Potential Way to Hit Elusive Target in Pancreatic CancerThree research groups have found a potential way to kill cancer cells in pancreatic tumors by simultaneously blocking the activity of proteins that interact with KRAS proteins and disrupting an energy-creating process called autophagy.
-
Atezolizumab Approved for Some Patients with Triple-Negative Breast CancerFDA has approved atezolizumab (Tecentriq) in combination with chemotherapy for the treatment of some women with advanced triple-negative breast cancer. This is the first FDA-approved regimen for breast cancer to include immunotherapy.
-
Trial Examines Value of Lymph Node Surgery in Advanced Ovarian CancerSurgery to remove all the lymph nodes in the area around an advanced ovarian tumor did not improve survival in a recent randomized clinical trial. The study also found systematic lymphadenectomy was associated with more frequent serious complications.
-
Targeted Therapy–Immunotherapy Combinations Effective for Advanced Kidney CancerIn two clinical trials, combination treatments that included an immune checkpoint inhibitor and axitinib (Inlyta) led to better outcomes for patients with advanced kidney cancer than treatment with sunitinib (Sutent), the standard initial therapy.
-
Darolutamide Delays the Spread of Some Prostate CancersThe investigational drug darolutamide can help delay the spread of prostate cancer in some men with the disease, a recent clinical trial shows. In addition, the drug caused fewer side effects than similar prostate cancer drugs.
-
Multipronged Approach Eliminates Racial Disparities in Early-Stage Lung Cancer TreatmentUse of a multipronged approach within hospitals, including community centers, not only eliminated treatment disparities among black and white patients with early-stage lung cancer, it also improved treatment rates for all patients, results from a new study show.
-
NCI’s Rare Cancer Clinics: Engaging Patients and Fostering CollaborationNCI has created special clinics that bring together clinicians, patients, and advocates to promote more rapid progress against rare cancers. The effort includes both rare pediatric cancers and central nervous system tumors in adults.
-
Treatment for Children with Leukemia Also Effective for Adolescents, Young AdultsA clinical trial found that an intensive treatment regimen developed specifically for children with acute lymphoblastic leukemia is also effective for older adolescents and young adults with the disease.